The oncological challenges posed by cancer cachexia, a condition that results in profound weight loss, muscle degeneration, and altered metabolism, are indeed staggering. Development of models for cancer cachexia at Protheragen supports all facets of cancer research, from bench to bedside and beyond into preclinical phases of drug development.
Overview of Cancer Cachexia Models
Cachexia is a multifaceted syndrome involving unintentional progressive weight loss stemming from muscle and fat tissue breakdown. Unlike simple malnutrition, this condition is unresponsive to conventional dietary interventions. It manifests in nearly 80% of individuals suffering from advanced cancers, specifically pancreatic, gastric, colorectal, and lung tumors. In addition to its effect on quality of life, cachexia severely hinders treatment efficacy and contributes to around 20% of cancer-associated mortality.
Fig.1 Summary graph of the preclinical model of cancer cachexia. (Li L.,
et al., 2024)
Current State of Cancer Cachexia Models
The area concerning creating models for cancer cachexia has evolved rapidly in the last few years. Older models, like tumor-bearing mice, are being improved upon to better mimic the human condition. Genetically engineered and humanized models are now more readily available to study the specific pathways, both genetic and molecular, that underlie cachexia. Also, the understanding of the changes that happen in parallel with cachexia on a systems level has improved due to the incorporation of omics technologies.
Table 1. The inoculated graft model of cancer cachexia. (Li L., et al., 2024)
| Inoculated graft model |
Strain |
Cell |
Cell numbers per animal |
Mouse age |
Inoculation method |
| Allograft models |
C57BL/6 |
LLC |
5×105–1×106 cells |
6–8 weeks |
Subcutaneously |
| BALB/c CD2F1 |
C26 |
5×105–1×106 cells |
6–8 weeks |
Subcutaneously |
| Wistar rats |
Walker 256 |
2×106–2×107 cells |
90 days |
Subcutaneously |
| C57BL/6 |
CHX307 |
1×106 cells |
10–11 weeks |
Intramuscularly |
| Wistar rats |
AH-130 |
108 cells |
7 weeks |
Intraperitoneally |
| Xenograft models |
NSG mice |
ES-2 |
1× 107 cells |
|
Intraperitoneally |
| ICR-Prkdc mice |
HT-1080 |
5×106 cells or
5×106 cells |
8–12 weeks |
Subcutaneously or heterotopically |
Our Services
Protheragen's cancer cachexia model development services stand out because of a number of differentiating characteristics. Our models are created with precision to simulate the clinical polysystems of cachexia, which include but are not limited to: weight reduction, muscle wasting, and other associated metabolic changes. We use an integrated oncology and metabolism as well as immunology approach to provide holistic explanations through all our multidisciplinary services. Customizability is one of the greatest features of our services, enabling clients to adjust models according to their unique queries.
Types of Cancer Cachexia Models
| Model Type |
Description |
Applications |
| Allograft Models |
Rodent-derived cancer cells implanted into syngeneic hosts (e.g., C26, LLC) |
Cytokine studies, muscle wasting dynamics |
| Xenograft Models (CDX, PDX) |
Human tumor cell lines or tissues implanted into immunodeficient mice (e.g., HT1080, ES-2, pancreatic PDX) |
Translational research, immune checkpoint inhibitor testing |
| Genetically Engineered Mouse Models |
Transgenic mice with targeted mutations (e.g., ApcMin/+, KrasG12D, Trp53R172H) |
Mechanistic studies, long-term therapeutic evaluation |
| Chemotherapy-Induced Models |
Induction of cachexia using agents such as DOX, Cisplatin, or 5-FU |
Study of treatment-associated muscle loss |
Multi-Tiered Approach to Model Customization
- Model Design and Selection: Based on tumor type, therapy target, and study timeline
- Animal Model Establishment: From cell line implantation to advanced PDX propagation
- Phenotypic Evaluation: Weight loss tracking, food intake, grip strength, histology
- Molecular Characterization: ELISA, qPCR, RNA-seq, mitochondrial, and inflammatory profiling
- Therapeutic Validation: Administration and evaluation of anti-cachexia candidates
- Custom Study Design: Flexible endpoints, route of administration, and combined treatment setups
Choosing Protheragen for cancer cachexia model development offers several distinct advantages. Our extensive experience in the field ensures that our models are grounded in the latest scientific knowledge. Our commitment to innovation means that we continuously integrate new technologies and methodologies into our services. Our team of experts is dedicated to providing exceptional customer support, from initial consultation to final reporting. If you are interested in our services, please feel free to contact us.
Reference
- Li, Li, et al. "A comprehensive review of animal models for cancer cachexia: Implications for translational research." Genes & Diseases 11.6 (2024): 101080.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
